
Axcelead Drug Discovery Partners株式会社
Japan axcelead.com From their website, Nov 2026
Work here? Claim this listing
About
Axcelead Drug Discovery Partners株式会社 is a drug discovery partner that supports pharmaceutical companies, biotech firms, and academic researchers. It provides integrated discovery services in Japan, covering target validation, hit finding, lead optimization, nonclinical development, and related biology, chemistry, pharmacology, and ADMET work.
Services
プロジェクト共創型ソリューション
Works with clients through discussion and shared problem-solving across target identification, hit finding, lead creation, lead optimization, candidate selection, and nonclinical development.
キナーゼプラットフォーム
Provides kinase-focused discovery tools, including focused libraries, kinase panel data, and selective tool compounds to accelerate early kinase drug discovery.
ドラッグリポジショニング
Uses public databases and fingerprinting data to identify candidate indications for existing, developing, or discontinued compounds and supports target validation.
遺伝子改変マウス・ラット作製
Creates and breeds KO and KI mice and rats using ES cell homologous recombination and CRISPR/Cas9, with downstream phenotypic and pharmacology/pathology evaluation.
オミックス
Performs multi-omics analyses for mechanism exploration, biomarker discovery, bioinformatics, single-cell and single-nucleus analysis, and spatial transcriptomics.
病理・生化学
Supports pathology peer review, image-based efficacy evaluation, laser microdissection, and assays for liver and kidney injury and miRNA analysis.
スクリーニング
Manages compound libraries and conducts HTS, HT-ASMS, phenotype-based screening, and iPS cell-based compound screening.
化学
Provides medicinal chemistry, computational chemistry, parallel synthesis, analytical chemistry, synthetic chemistry, and flow chemistry.
8 more services
- 薬物動態
- 安全性
- がん関連創薬支援
- 免疫疾患関連創薬支援
- 神経・筋疾患関連評価
- 腎疾患関連創薬支援
- 代謝疾患関連創薬支援
- 心血管疾患関連創薬支援
- Turnaround
- 9ヶ月
- 12ヶ月
- 6ヶ月
- 約3ヶ月
- What to send
- お客様がご興味のある遺伝子名
- お手持ちの化合物の創薬ターゲット情報
Capabilities
- Assays and studies
- HTS
- In vivo
- PK/PD
- ADME
- ADCs
- HPLC
11 more
- HT-ASMS
- TR-FRET kinase panel assay
- In vitro assay
- In vivo assay
- ADMET screening
- hERG assay
- Single-cell analysis
- Single-nucleus analysis
- PK/PD analysis
- EC50/IC50 measurement
- ADCC activity assay
- Scale and capacity
- 150万以上の化合物ライブラリ
- 約5,000化合物のKinase Focused Library
- 約3ヶ月で20匹以上のhomo KOマウス・ラット
- 1匹の雄性KO/KIマウスから約半年で50匹以上のHomo KO/KIマウス
- 最大40kbpのKIマウス
- 最大17kbpのKIマウス
Instruments and platforms
- IVIS
- HPLC
- Chiral HPLC
- NMR
- Syncropatch
Modalities and species
- Modalities
- ADC
- Oligonucleotide
- mRNA
- Gene editing
- Species and models
- Rat
- KO rat
- KI rat
- Xenograft model
- PDx model
- Syngeneic model
Certifications
As the company states them, with the certificate or registry record where there is one.
GLPSelf-reported
Details
- Type
- CRDMO
- Founded
- 2017
- Quality
- BSL2 (HTS) · IND・NDA (試験および申請対応)
- Based in
- Japan
Public records
- Biocom California CRO directory
- Candidate Generation, drug discovery, High Throughput Screening, IND enabling studies, Non-clinical pharmacology/DMPK/safety studies source